1-(4-甲氧基-苄基)-1H-吡唑 | 145162-51-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(4-甲氧基-苄基)-1H-吡唑
• 英文名称: 1-(4-methoxybenzyl)-1H-pyrazole
• 英文别名: 1-(p-methoxyphenyl)methyl-pyrazole；1-[(4-methoxyphenyl)methyl]pyrazole
• CAS: 145162-51-2
• 化学式: C₁₁H₁₂N₂O
• 分子量: 188.229
• InChiKey: DFJJBKFWYFQQIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933199090

反应信息

• 作为反应物：
  描述：

  1-(4-甲氧基-苄基)-1H-吡唑 在 三氯氧磷 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 16.0h， 以35%的产率得到1-(4-甲氧基苄基)-1H-吡唑-4-甲醛
  参考文献：
  名称：

  [EN] HETEROARYLAMINO-PHENYLKETONE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS
  [FR] DERIVES D'HETEROARYLAMINO-PHENYLCETONE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE KINASES

  摘要：

  本发明涉及抑制VEGF受体酪氨酸激酶，特别是KDR的化合物，包含这种化合物的药物组合物，使用这种化合物和组合物治疗哺乳动物中依赖VEGF受体激酶的疾病和病况的方法，以及其制造方法。

  公开号：

  WO2005000813A1
• 作为产物：
  描述：

  3-{N'-[1-(4-Methoxy-phenyl)-meth-(E)-ylidene]-hydrazino}-propionitrile 在 sodium butanolate 作用下， 以 正丁醇 为溶剂， 反应 3.0h， 生成 1-(4-甲氧基-苄基)-1H-吡唑
  参考文献：
  名称：

  Non-Nucleoside Inhibitors of BasE, an Adenylating Enzyme in the Siderophore Biosynthetic Pathway of the Opportunistic PathogenAcinetobacter baumannii

  摘要：

  Siderophores are small-molecule iron chelators produced by bacteria and other microorganisms for survival under iron limiting conditions such as found in a mammalian host. Siderophore biosynthesis is essential for the virulence of many important Gram-negative pathogens including Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli. We performed high-throughput screening against BasE, which is involved in siderophore biosynthesis in A. baumannii, and identified 6-phenyl-1-(pyridin-4-ylmethyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid 15. Herein we report the synthesis, biochemical, and microbiological evaluation of a systematic series of analogues of the HTS hit 15. Analogue 67 is the most potent analogue with a K-D of 2 nM against BasE. Structural characterization of the inhibitors with BasE reveals that they bind in a unique orientation in the active site, occupying all three substrate binding sites, and thus can be considered as multisubstrate inhibitors. These results provide a foundation for future studies aimed at increasing both enzyme potency and antibacterial activity.

  DOI：

  10.1021/jm301709s

文献信息

• [EN] NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX DÉRIVÉS DE THIÉNOPYRIMIDINE, PROCÉDÉ POUR LEUR PRÉPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：SERVIER LAB

  公开号：WO2015097123A1

  公开（公告）日：2015-07-02

  Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.

  式（I）的化合物：其中R1、R2、R3、R4、R5、R6、R7、R12、X、A和n的定义如描述中所述。
• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：PHARMACYCLICS LLC

  公开号：WO2016004272A1

  公开（公告）日：2016-01-07

  Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了抑制布鲁顿酪氨酸激酶（Btk）的化合物。还描述了Btk的不可逆抑制剂。此外，还描述了Btk的可逆抑制剂。还披露了包括这些化合物的药物组合物。披露了使用Btk抑制剂的方法，单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症（包括淋巴瘤）和炎症性疾病或症状。
• Boron carbonitride photocatalysts for direct decarboxylation: the construction of C(sp³)–N or C(sp³)–C(sp²) bonds with visible light
  作者：Jiale Shi、Tao Yuan、Rong Wang、Meifang Zheng、Xinchen Wang

  DOI：10.1039/d1gc00922b

  日期：——

  functionalization of acids via metal-free boron carbon nitride (BCN) photocatalysis, delivering the desired products under ambient conditions. This methodology is applicable to the late-stage modification of pharmaceutical molecules and gram-scale experiments as well as in the recovery and reuse of the photocatalysts without the loss of reactivity. The developed photochemical reaction system fulfills the requirements

  建立了无金属规程，用于通过无金属氮化硼碳氮化物（BCN）光催化对酸进行脱羧N-H或C（sp 2）-H官能化，从而在环境条件下提供所需的产物。该方法学适用于药物分子的后期修饰和克级实验，以及光催化剂的回收和再利用而不损失反应性。开发的光化学反应系统满足绿色和可持续化学的要求。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017012576A1

  公开（公告）日：2017-01-26

  Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis(ALS).

  揭示了一种抑制LRRK2激酶活性的新化合物，以及它们的制备方法、含有它们的组合物以及它们在治疗或预防由LRRK2激酶活性特征的疾病中的应用，例如帕金森病、阿尔茨海默病和肌萎缩侧索硬化症（ALS）。
• Synthesis and structure–activity relationship of a novel series of heterocyclic sulfonamide γ-secretase inhibitors
  作者：Jun Pu、Anthony F. Kreft、Suzan H. Aschmies、Kevin P. Atchison、Joshua Berkowitz、Thomas J. Caggiano、Micheal Chlenov、George Diamantidis、Boyd L. Harrison、Yun Hu、Donna Huryn、J. Steven Jacobsen、Mei Jin、Kerri Lipinski、Peimin Lu、Robert L. Martone、Koi Morris、June Sonnenberg-Reines、Dave R. Riddell、Joan Sabalski、Shaiu-Ching Sun、Erik Wagner、Yiqun Wang、Zheng Xu、Hua Zhou、Lynn Resnick

  DOI：10.1016/j.bmc.2009.04.052

  日期：2009.7

  the production of β-amyloid, a component of the plaques that are found in brains of patients with Alzheimer’s disease. A novel series of heterocyclic sulfonamide γ-secretase inhibitors that reduce β-amyloid levels in cells is reported. Several examples of compounds within this series demonstrate a higher propensity to inhibit the processing of amyloid precursor protein compared to Notch, an alternative

  业已证明，γ-分泌酶抑制剂可减少β-淀粉样蛋白的产生，β-淀粉样蛋白是在阿尔茨海默氏病患者的大脑中发现的斑块的一种成分。据报道，一系列新的杂环磺酰胺γ-分泌酶抑制剂可降低细胞中的β-淀粉样蛋白水平。与Notch（一种替代的γ-分泌酶底物）相比，该系列化合物的几个实例显示出更高的抑制淀粉样蛋白前体蛋白加工的倾向。